Supported by: Richard Lyle*, Stuart McMillan*, Edward Mountain*, Bill Kidd*, Kenneth Gibson*, Monica Lennon* Wednesday 1 May 2019 17 Today's Business Future Business Motions & Questions Legislation Other Gnothaichean an-diugh Gnothaichean ri teachd Gluasadan agus Ceistean Reachdas Eile Motions | Gluasadan *S5M-17106 Angela Constance: Scottish Cancer Patient Experience Survey—That the Parliament welcomes the results of the second Scottish Cancer Patient Experience Survey (SCPES), which is jointly funded by the Scottish Government and Macmillan Cancer Support; notes that around 5,000 people gave feedback on various aspects of their care, including diagnosis, treatment and support; supports the findings that show 95% of those surveyed rated their overall care highly, which is up from 94% in 2015; notes that 83% thought their first appointment with a hospital doctor was as soon as necessary, with 87% agreeing that their options were completely explained before their treatment started; acknowledges that the survey highlights areas where improvements can be made, including directing more people to emotional and financial support during their treatment; considers that the survey results contain valuable insights for stakeholders to use to improve cancer services across the whole cancer journey, from detection through to treatment and beyond; thanks everyone who took the time to complete the survey, and encourages NHS boards to listen to what people with cancer are saying about what matters to them Supported by: Sandra White*, Richard Lyle*, Stuart McMillan*, Alex Neil*, Bill Kidd*, Kenneth Gibson*, Mark McDonald*, Jenny Gilruth*, Fulton MacGregor* Alexander Stewart: Bladder Cancer Awareness Month—That the Parliament *S5M-17105 acknowledges that May 2019 is Bladder Cancer Awareness Month; is concerned at what it sees as the relative lack of knowledge and awareness across Scotland and the UK among general public and some areas of the medical profession regarding bladder cancer and its symptoms; is further concerned that the service that patients receive, it believes, very much varies depending not only on the different health authorities responsible for their care but medical professionals’ knowledge and awareness of the symptoms; considers that this is not a rare cancer as it is the fourth most common in men in the UK and the seventh overall; understands that treatments have hardly changed in the past 30 years, that there is little research investment, and that outcomes for patients are, by comparison with other common cancers, still poor; is saddened that more than 62% of those diagnosed will die...